Table 1.
Patients’ baseline characteristics
| Osimertinib | Gefitinib | |
|---|---|---|
| (n = 65) | (n = 55) | |
| Sex, n (%) | ||
| Male | 22 (33.8) | 27 (49.1) |
| Female | 43 (66.2) | 28 (50.9) |
| Age, years, median (range) | 67.0 (34–82) | 67.0 (43–85) |
| Smoking status, n (%) | ||
| Never-smokers | 35 (53.8) | 29 (52.7) |
| Current/former smokers | 30 (46.2) | 26 (47.3) |
| CNS metastases at study entry, n (%) | 14 (21.5) | 13 (23.6) |
| WHO performance status, n (%) | ||
| 0 (normal activity) | 38 (58.5) | 34 (61.8) |
| 1 (restricted activity) | 27 (41.5) | 21 (38.2) |
| Overall disease classification, n (%) | ||
| Metastatic | 60 (92.3) | 53 (96.4) |
| Locally advanced | 5 (7.7) | 2 (3.6) |
| EGFR mutationa at baseline, n (%) | ||
| Exon 19 deletion | 33 (50.8) | 30 (54.5) |
| L858R | 32 (49.2) | 25 (45.5) |
CNS, central nervous system; EGFR, epidermal growth factor receptor; WHO, World Health Organization.
aEGFR mutations based on the test (local or central) used to determine randomization strata.